AnalystBook Research · Company Intelligence

ALCON INC

ALCNYSE

Built from ALCON INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 20-F · headline figures audited against SEC data

Alcon, the largest eye care company, grew revenue 4.9% to $10.40B and free cash flow 7.7% to $1.73B, while launch spending, research, tariffs and acquisitions cut operating margin 118 bps to 13.08%

The read at a glance✓ Audited against SEC data
  • Growth — Revenue up 4.9% to $10.40B; Vision Care up 6%, Surgical up 4%OK
  • Profitability — Operating margin down 118 bps to 13.08%; net income down 3.7% to $980MWatch
  • Balance sheet — $4.7 billion of debt, 97% fixed rate; equity up 2.2% to $22.03BOK
  • Accounting quality — Forensic scores not available for FY2025; PwC auditor since 2019Note
  • Capital allocation — Dividends up 28.2% to $168M; $682 million of buybacks in 2025Note
  • Market position — Number one by global share in both ophthalmic surgical and vision careOK

Business

Alcon makes and sells eye care products in two segments. Surgical, $5,751 million of 2025 net sales, supplies intraocular lenses, consumables and equipment for cataract, retinal, refractive and glaucoma surgery, using the largest installed base of surgical equipment to pull through consumables and lenses. Vision Care, $4,568 million, sells contact lenses and ocular health products such as Systane and Pataday. The United States was 45% of net sales.

Latest filings

  • 6-K · Company announcement (foreign filer)2026-08-10
  • 6-K · Company announcement (foreign filer)2026-05-05
  • 6-K · Company announcement (foreign filer)2026-04-02
  • 6-K · Company announcement (foreign filer)2026-02-24
  • 6-K · Company announcement (foreign filer)2026-02-24
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ALCON INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full ALC record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.